| Organism | Drug Class | Sponsor and/or Company | Drug Name | Alt Name | Drug Status | Notes | AIDS# |
| Aspergillus spp. | Combination | Pfizer | Eraxis™ and Vfend™ | Anidulafungin and Voriconazole | Phase 3 | Completed |
549947
|
| Aspergillus spp. | Wall/Membrane Disruptor | Basilea Pharmaceutica | Cresemba™ | Isavuconazole; ASP9766; BAL-4815; BAL-8557(pro-drug) | FDA Approved in 2015 | |
416566
|
| Aspergillus spp. | Wall/Membrane Disruptor | Gilead Sciences; Nexstar Pharmaceuticals | Nebulised Ambisome™ | Nebulised Liposomal Amphotericin B | Phase 2/3 | Recruiting |
000096
|
| Aspergillus spp. | Wall/Membrane Disruptor | Kaken Pharmaceutical Co. | SPK-843 | SPA-S-843 | Phase 3 | Unknown |
121440
|
| Candida spp. | Cell wall synthesis inhibitor | Scynexis, Inc. | SCY-078 | MK-3118 | Phase 2 | Recruiting | |
| Candida spp. | Combination | Almirall, S.A. | LAS41003 | LAS189962 and LAS189961 | Phase 2 | Completed | |
| Candida spp. | Combination | MethylGene | MGCD290 and Fluconazole | MG-3290 and Fluconazole | Phase 2 | Completed |
496028
|
| Candida spp. | Enhance inflammatory response | AM-Pharma | Human Lactoferrin | hLF1-11 | Phase 1/2 | Terminated |
028450
|
| Candida spp. | Leucyl-tRNA synthetase inhibitor | Anacor Pharmaceuticals | AN-2718 | | Phase 1 | Completed |
471686
|
| Candida spp. | Sterol demethylase inhibitor | Palau Pharma/GlaxoSmithKline | Albaconazole | UR-9825, W-0027 | Phase 2 | Completed |
024107
|
| Candida spp. | Sterol demethylase inhibitor | Viamet Pharmaceuticals, Inc. | VT-1161 | | Phase 2 | Completed | |
| Candida spp. | Wall/Membrane Disruptor | Ferrer Internacional S.A. | Arasertaconazole | R-isomer of Sertaconazole | Phase 2 | Completed |
008889
|
| Candida spp. | Wall/Membrane Disruptor | Pacgen Biopharmaceuticals | PAC-113 | | Phase 2 | Completed | |
| Cryptococcus spp. | Unknown | Alkermes | Lobradimil | RMP-7 | Phase 1 | Completed | |
| Cryptococcus spp. | Wall/Membrane Disruptor | Schering-Plough | Genaconazole | SCH 39304; SM-8668 | Phase 1 | Completed |
007341
|
| Cryptococcus spp. | Wall/Membrane Disruptor | Kaken Pharmaceutical Co.; Proaparts srl | SPK-843 | SPA-S-843 | Phase 3 | Unknown |
121440
|
| Pneumocystis jirovecii | Combination | GlaxoSmithKline | Clindamycin and Primaquine | | Phase 3 | Completed |
000295
|
| Pneumocystis jirovecii | Combination | GlaxoSmithKline | Dapsone and Trimethoprim | | Phase 3 | Completed |
000310
|
| Pneumocystis jirovecii | DNA Synthesis Inhibitor | Immtech Pharmaceuticals, Inc | Pafuramidine maleate | DB289; Prodrug of DB75 | Phase 3 | Terminated |
022387
|
| Pneumocystis jirovecii | Succinate Dehydrogenase Inhibitor | GlaxoSmithKline | Sitamaquine | WR 6026 | Phase 2 | Completed |
007904
|